FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286314124> ?p ?o ?g. }

• W4286314124 endingPage "S158" @default.
• W4286314124 startingPage "S157" @default.
• W4286314124 abstract "Heart failure (HF) patients with implantable devices have improved outcomes on optimal Guideline-Directed Medical Therapy (GDMT), yet few studies have evaluated the impact of mineralocorticoid receptor antagonists (MRA) on mortality and arrythmia risk in patients who may be unable to tolerate optimal GDMT. To assess the impact of MRA use on the risk of all-cause mortality and ventricular tachyarrhythmia (VTA) in HF patients with an ICD or CRT-D who were not concomitantly treated with both beta blockers (BB) and ACE-inhibitors/angiotensin receptor blockers (ACE/ARB) in 4 MADIT (Multicenter Automatic Defibrillator Implantation Trial; MADIT-II, MADIT-CRT, MADIT-RIT, MADIT-RISK) and Ranolazine in High-Risk Patients with ICD (RAID) clinical trials. We included 5504 patients enrolled in 5 landmark ICD clinical trials. Patients were categorized by MRA use in addition to baseline BB and/or ACE/ARB use into subgroups of those who were prescribed both BB and ACE/ARB (2-drug GDMT) and those who were prescribed only one of the two drugs (1-drug GDMT) at enrollment. Cox proportional hazards regression models and Fine and Gray regression models, stratified by studies, were performed to assess the association between time-dependent MRA use and risks of all-cause mortality and VTA. VTA was defined as any treated or monitored sustained ventricular tachycardia (≥170 bpm) or ventricular fibrillation. Among 5504 study patients, 4392 (80%) were prescribed 2-drug GDMT and 1016 (18%) were prescribed 1-drug GDMT. MRA was prescribed to 1656 (30%) patients. Multivariate analysis demonstrated that MRA use was associated with a 52% reduction in mortality risk when prescribed in patients on 1-drug GDMT (HR=0.48 [95% CI: 0.27-0.86], p=0.014). The mortality benefit of MRA therapy was attenuated among patients on 2-drug GDMT (HR=1.05 [95% CI: 0.82-1.34], p=0.7) (Figure 1). Further, MRA use was associated with a 36% reduction in VTA risk in patients on 1-drug GDMT (HR=0.64 [95% CI: 0.40-1.01], p = 0.05), while among patients on 2-drug GDMT the association of MRA use with VTA risk was also attenuated (HR=1.09 [95% CI: 0.93-1.29], p=0.28) (Figure 2). In HF patients with an ICD or CRT-D who are unable to tolerate 2-drug GDMT, MRA use is associated with a reduction in the risk of mortality and VTA.View Large Image Figure ViewerDownload Hi-res image Download (PPT)" @default.
• W4286314124 created "2022-07-21" @default.
• W4286314124 creator A5002121570 @default.
• W4286314124 creator A5003713306 @default.
• W4286314124 creator A5008613276 @default.
• W4286314124 creator A5029885472 @default.
• W4286314124 creator A5033296220 @default.
• W4286314124 creator A5050985894 @default.
• W4286314124 creator A5055222260 @default.
• W4286314124 creator A5059052503 @default.
• W4286314124 creator A5071176966 @default.
• W4286314124 creator A5077082770 @default.
• W4286314124 creator A5080676116 @default.
• W4286314124 date "2022-05-01" @default.
• W4286314124 modified "2023-09-26" @default.
• W4286314124 title "PO-628-03 ASSOCIATION OF MINERALOCORTICOID RECEPTOR ANTAGONIST USE WITH MORTALITY AND VENTRICULAR ARRHYTHMIA RISK IN PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS" @default.
• W4286314124 doi "https://doi.org/10.1016/j.hrthm.2022.03.880" @default.
• W4286314124 hasPublicationYear "2022" @default.
• W4286314124 type Work @default.
• W4286314124 citedByCount "0" @default.
• W4286314124 crossrefType "journal-article" @default.
• W4286314124 hasAuthorship W4286314124A5002121570 @default.
• W4286314124 hasAuthorship W4286314124A5003713306 @default.
• W4286314124 hasAuthorship W4286314124A5008613276 @default.
• W4286314124 hasAuthorship W4286314124A5029885472 @default.
• W4286314124 hasAuthorship W4286314124A5033296220 @default.
• W4286314124 hasAuthorship W4286314124A5050985894 @default.
• W4286314124 hasAuthorship W4286314124A5055222260 @default.
• W4286314124 hasAuthorship W4286314124A5059052503 @default.
• W4286314124 hasAuthorship W4286314124A5071176966 @default.
• W4286314124 hasAuthorship W4286314124A5077082770 @default.
• W4286314124 hasAuthorship W4286314124A5080676116 @default.
• W4286314124 hasConcept C126322002 @default.
• W4286314124 hasConcept C164705383 @default.
• W4286314124 hasConcept C2778198053 @default.
• W4286314124 hasConcept C2781005686 @default.
• W4286314124 hasConcept C71924100 @default.
• W4286314124 hasConceptScore W4286314124C126322002 @default.
• W4286314124 hasConceptScore W4286314124C164705383 @default.
• W4286314124 hasConceptScore W4286314124C2778198053 @default.
• W4286314124 hasConceptScore W4286314124C2781005686 @default.
• W4286314124 hasConceptScore W4286314124C71924100 @default.
• W4286314124 hasIssue "5" @default.
• W4286314124 hasLocation W42863141241 @default.
• W4286314124 hasOpenAccess W4286314124 @default.
• W4286314124 hasPrimaryLocation W42863141241 @default.
• W4286314124 hasRelatedWork W1998556240 @default.
• W4286314124 hasRelatedWork W2012241433 @default.
• W4286314124 hasRelatedWork W2039995053 @default.
• W4286314124 hasRelatedWork W2076843464 @default.
• W4286314124 hasRelatedWork W2096105382 @default.
• W4286314124 hasRelatedWork W2125804349 @default.
• W4286314124 hasRelatedWork W2304633692 @default.
• W4286314124 hasRelatedWork W4237806278 @default.
• W4286314124 hasRelatedWork W4247718175 @default.
• W4286314124 hasRelatedWork W4313444034 @default.
• W4286314124 hasVolume "19" @default.
• W4286314124 isParatext "false" @default.
• W4286314124 isRetracted "false" @default.
• W4286314124 workType "article" @default.